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Abstract
Background: Field surveys conducted in China before the implementation of the essential medicine policy showed
that Chinese individuals faced less access to essential medicines. This paper aims to evaluate the availability, prices
and affordability of essential medicines in Jiangsu Province, China after the implementation of the policy in 2009.
Methods: A cross-sectional survey was conducted in Jiangsu in 2013 using the World Health Organization/Health
Action International (WHO/HAI) methodology. Data on the availability and prices of 50 essential medicines were
collected from the public and private healthcare sectors.
Results: The mean availabilities of innovator brands and lowest priced generics (LPGs) were 11.5 % and 100 % in
primary healthcare facilities, 36.8 % and 32.6 % in the secondary and tertiary sectors, and 18.7 % and 42.9 % in the
private sector, respectively. The median price ratios (MPRs) were 1.26 to 2.05 for generics and 3.76 to 27.22 for
innovator brands. Treating ten common diseases with LPGs was generally affordable, whereas treatment with IBs
was less affordable.
Conclusions: The high availability of LPGs at primary healthcare facilities reflects the success of the essential
medicine policy, while the low availability in secondary and tertiary levels and in private pharmacies reflects a
failure to implement the policy in these levels. The health policy should be fully developed and enforced at the
secondary and tertiary levels and in the private sector to ensure equitable access to health services.
Background
According to a report issued by the World Health
Organization (WHO), approximately one-third of the
global population lacks reliable access to needed medi-
cines [1]. Access to healthcare is a fundamental human
right that has been enshrined in international treaties
and recognized by governments around the world. How-
ever, the fundamental right to health cannot be fulfilled
without equitable access to essential medicines for prior-
ity diseases, particularly for people in developing coun-
tries with poor medical supplies [2].
China is also confronted with less access to essential
medicines. A field survey conducted in Shandong and
Gansu provinces in 2007 revealed that the median avail-
ability of surveyed medicines in hospital pharmacies
ranged from 19 to 69 % [3]. Moreover, the Chinese people
have suffered from inaccessible and unaffordable health
services for decades. By the end of 2012, there were still
80,512,000 people, comprising approximately 6 % of the
population, who lacked access to health services. In
addition, government health expenditures accounted for
approximately 5 % of GDP, with drug expenditures com-
prising up to 40 % of total health expenditures [4], among
the highest proportions in the world [5]. To address the
foregoing problems, the central government officially
launched a new healthcare reform in 2009, one pillar of
which was to establish a National Essential Medicine
System (NEMS) to satisfy the public’s basic healthcare
needs. The NEMS requires all primary health care institu-
tions (namely, urban community health care centers,
rural township hospitals, and village clinics) that receive
government subsidies to stock and dispense all essential
medicines at zero markup. Other types of medical organi-
zations, such as secondary and tertiary hospitals and
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private hospitals, are expected to provide essential medi-
cines as priority drugs for patients and ensure a certain
use proportion that would vary according to local eco-
nomic development [6]. Since the initiation of the NEMS
in 2009, only one study has been conducted, in Shaanxi
province in 2010, utilizing the Health Organization/
Health Action International (WHO/HAI) methodology to
review the prices, availability, and affordability of medi-
cines [7]. Hence, this is the second study of this type
since the essential medicine policy was implemented in
China and the first conducted in Jiangsu province. The
Essential Medicines List (EML) used in this survey is one
latest Jiangsu Provincial EML in 2011, because for each
province the EML is different.
Throughout China, public healthcare facilities are offi-
cially divided into three levels based on quality and
levels of service: tertiary, secondary and primary. A
higher level indicates better services. In addition, these
facilities can be classified into public and private accord-
ing to their nature. In China, patients can buy drugs
from either public or private facilities. According to sta-
tistics from the provincial Department of Health in
Jiangsu, annual per capita medical expenses paid by pa-
tients amounted to 221.2 CNY for outpatients and
10864.3 CNY for inpatients in 2013 and pharmaceutical
expenditures accounted for 48.60 % and 43.24 %, re-
spectively [8]. Therefore, it would be of strategic and
practical significance to investigate whether the imple-
mentation of this health reform in Jiangsu has been ef-
fective. This study assesses medicine availability, prices
and affordability in Jiangsu by collecting data from five
of its cities. Particular attention is paid to the innovator
brands (IBs) and lowest-priced generics (LPGs) available
in Jiangsu and different types of medicine outlets (public
hospitals and private pharmacies).
Methods
We conducted a survey of the availability, prices and af-
fordability of the essential medicines in Jiangsu, China by
adopting the standardized WHO/HAI methodology [9,
10], which was modified as per the requirement of the
study done at one province of China [11]. All data from
this survey were collected from March 2013 to May 2013.
Survey scope and medicine outlets
Jiangsu Province, located in eastern China, has a popula-
tion of 78.98 million and 13 cities. Nanjing is the capital.
Five representative cities of this province, rather than six
as recommended by the WHO/HAI methodology, were
selected as survey areas for data collection: Nanjing,
Suzhou, Yangzhou, Suqian, and Yancheng. The selected
cities are reachable within one day of travel from the
capital and provide a large enough sample to represent
the province.
In each survey area, the sample of public hospitals was
identified by first selecting the main public hospital. An
additional four public medicine outlets per survey area
were then randomly selected from those within a four-
hour drive from the main hospital. Most tertiary hospi-
tals and medical resources are concentrated in the
capital city, Nanjing, and few tertiary hospitals are in
other cities. Therefore, 2 tertiary hospitals were selected
in Nanjing, and no tertiary hospitals were selected in
other cities. Additionally, there are relatively few primary
healthcare facilities in Nanjing. Therefore, to make the
sample more representative and consistent with the dis-
tribution of medical resources in Jiangsu Province, 2 ter-
tiary and 3 secondary hospitals were selected in Nanjing,
whereas 2 secondary and 3 primary hospitals were se-
lected from each other cities. The public sector sample
therefore contained five public medicine outlets in each
of the five cities, yielding 25 public outlets. The sampled
hospitals are all general, covering both urban and rural
areas and serving approximately 142,290 patients on
average each year. The private sector sample was deter-
mined by selecting the licensed private pharmacies clos-
est to each of the selected public medicine outlets.
Specifically, two private pharmacies near each secondary
and tertiary healthcare facility were selected according
to the recommendation of the methodology, but only
one private pharmacy near each primary healthcare facil-
ity was selected due to the lack of nearby pharmacies,
yielding 38 private outlets (See Table 1). The sample rep-
resented all retail pharmacies in each city. All the se-
lected medicine outlets agreed to participate in the
study, and a written informed consent form was signed
before data collection.
Table 1 Main characteristics of the five selected survey areas in 2013
City/county Nanjing (Capital) Suzhou Yangzhou Suqian Yancheng
Economic status High-income High-income Medium-income Low-income Low-income
Geographic position Southwest Southeast Center Northwest Northeast
NO. of Public hospitals 2 tertiary 2 secondary 2 secondary 2 secondary 2 secondary
3 secondary 3 primary 3 primary 3 primary 3 primary
NO. of Private pharmacies Two private pharmacies near the secondary and tertiary healthcare facilities and one private pharmacy near primary healthcare
facilities
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Selection of medicines
The WHO/HAI methodology requires a systematic
survey of the prices of core and supplementary lists of
medicines that are selected by each country according
to local priorities in treating national health problems.
Initially, 30 core medicines listed by WHO/HAI and 40
supplementary medicines were selected for inclusion in
the survey. Following a pilot study, the list of medi-
cines was modified because 7 core medicines were not
on the EML, or not permitted to be used in general
hospitals or sold in private pharmacies, and many sup-
plementary medicines were also not on the list, or did
not have reference prices. Hence, 50 medicines were fi-
nally selected for this survey, including 23 core medi-
cines and 27 supplementary medicines. The former
represent medicines commonly used in the treatment
of a range of chronic and acute conditions, while the
latter are of local importance [12]. The names and
pack sizes of all medicines included on both lists (core
and supplementary) are provided in Additional file 1.
For each medicine, two forms (IBs and LPGs) were
surveyed. The manufacturers of IBs were easily identi-
fied because each IB has a unique manufacturer, while
those of LPGs were determined during data collection
at each facility.
Data collection
Prior to data collection, a one-week training was held
to provide area supervisors, data collectors and data
entry personnel with the knowledge and skills required
to conduct the medicine availability, prices and afford-
ability survey in an accurate and reliable manner. A
standardized data collection form was used to ensure
data reliability and consistency. Additionally, a local-
ized pilot study was conducted during the training in
Nanjing to verify the feasibility and effectiveness of the
survey.
Area supervisors made appointments with respon-
sible persons at the target healthcare centers before for-
mal data collection began to make it convenient for
researchers to collect information. Then, data collectors
visited each region separately to finish collection, and
area supervisors met with them in the field at the end
of each day to check completed data collection forms
and ensure that the data were complete, consistent and
legible. Data on the availability and patient prices of
medicines at the selected public hospitals and private
pharmacies were collected. The data collection was
completed within six weeks. Because human and ani-
mal clinical trials were not involved in this study, the
need for ethical review was waived by the Institutional
Review Board of China Pharmaceutical University,
China. This research adhered to the STROBE guide-
lines for observational studies (see Additional file 2).
Data entry and analysis
Data entry and analysis was facilitated by a standardized
computerized workbook for double entry to record the
data generated by the survey. We verified the data before
the unit prices were entered into the computerized
workbook provided by WHO/HAI [13]. All data were
entered twice, followed by software verification and val-
idation through “double entry” and “data checker” func-
tions to identify data entry errors. Furthermore, codes,
instead of the actual names, were used to identify these
public healthcare facilities and retail pharmacies to
maintain their anonymity.
Information on the availability and prices of medi-
cines in different geographic areas and healthcare sec-
tors was generated using the same software employed
for data analysis. The study endpoints focused on three
measures: medicine availability, prices and affordability.
Availability was defined as the proportion of pharma-
cies in which the medicines were available at the time
of the survey. The availabilities of both types of medi-
cines (IBs and LPGs) in public hospitals and private
pharmacies were calculated. Prices were presented as
median price ratios (MPR) in this study. The MPR is
the ratio of the median local unit price across facilities
divided by the median international reference unit price
(IRP). In this survey, medicine prices from the Drug
Prices Guide in 2011 issued by Management Science
for Health (MSH) were adopted as the IRPs for core
medicines, but because MSH prices were not available
for most supplementary medicines, Spanish manufac-
turers’ selling prices were used as their reference prices
(supplied by WHO/HAI project member Carmen
Peres-Casas). Spain is known to have relatively low
manufacturer selling prices. MPRs were only calculated
if the medicine was available at a minimum of four fa-
cilities. For the purposes of this discussion, we use the
following MPR cut-off points for patient prices to rep-
resent acceptable local price ratios: MPR ≤ 1.5 for pub-
lic hospital patient prices and MPR ≤ 2.5 for retail
pharmacies patient prices [14]. Affordability was esti-
mated by comparing the total cost of a medicine for a
standard course of treatment to the daily wage of the
lowest paid unskilled government worker, which was
42.7 CNY per day at the time of the survey [15].
Results
Availability
Public hospitals in this survey are divided into two cat-
egories: primary healthcare facilities and secondary and
tertiary healthcare facilities. Table 2 shows the mean
availability for public hospitals and retail pharmacies.
The availability of LPGs was 100 % at the primary facil-
ities, which was attributed to the NEMS requirements to
be stock all essential medicines. For IBs, however, only
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11.5 % were available in primary facilities, and only four
medicines—Amlodipine, Captopril, Ciprofloxacin and
Metformin—had >50 % availability.
The data also showed that the mean availability of
LPGs and IBs was 32.6 % and 36.8 %, respectively, in
secondary and tertiary facilities. Additionally, the mean
availability of LPGs and IBs was 42.9 % and 18.7 %, re-
spectively, in retail pharmacies (see Table 2). The avail-
ability of LPGs in these two types of outlets was lower
than that in primary facilities (100 %). In fact, only 7
LPGs in the secondary and tertiary facilities and 20 in
the retail pharmacies had >50 % availability. Addition-
ally, only 24 IBs in the secondary and tertiary facilities
and 4 in the retail pharmacies had >50 % availability. Al-
though the mean availability of IBs in the secondary and
tertiary facilities (36.8 %) was low, this value was the high-
est of the surveyed sectors. Overall, the highest availability
of LPGs (100 %) and the lowest of IBs (11.5 %) were ob-
served at primary healthcare facilities, whereas the IBs
were most available (36.8 %) and LPGs least available
(32.6 %) at secondary and tertiary facilities.
Patient prices
As shown in Table 3, the MPRs of all LPGs ranged from
1.26 to 2.05, which demonstrated that the patient prices
of LPGs approached the acceptable price line and were
similar to the IRPs. However, the patient prices of IBs
were all above the threshold level, with MPRs ranging
from 3.76 to 27.22. Moreover, the MPRs of most IBs in
public sector outlets were much higher (approximately 2
to 7 times higher) than those in private pharmacies
were.
One outlier drug was nifedipine sustained-release. This
drug, either in the form of LPGs or IBs, had high median
prices of, on average, 4 to 17 times the IRP in all sectors.
The greatest price difference (27.22 times the IRP) was
found for the IBs of supplementary medicines in primary
healthcare facilities.
Affordability
In view of the low availability of core medicines, we con-
sidered ten priority diseases to measure the affordability
of standard treatments. As shown in Table 4, the cost of
purchasing LPGs at all surveyed was between 0.1 and
0.8 days’ wages, which indicated that generic medicines
in Jiangsu Province were fairly affordable. The most af-
fordable LPGs were glibenclamide for treating diabetes
and atenolol for treating hypertension (which cost
0.1 days’ wages in all sectors). IBs, however, were less af-
fordable. When IBs were prescribed and dispensed in
the surveyed sectors, some treatments were surprisingly
costly. For example, treating hypercholesterolemia with
IB simvastatin would cost over 7 days’ wages, while
treating arthritis with IB diclofenac would cost 2 days’
wages. Overall, IB products were less affordable than
LPGs in both the public and private sectors.
Discussion
Our results indicate, first, the success of the essential
medicine policy because the availability of LPGs in pri-
mary care facilities has reached 100 %. According to sta-
tistics from the Ministry of Health in China, the visits to
primary outlets has reached 3.92 billion by November
2014, accounting for 57.9 % of the total visits. Therefore,
the success has enabled the population who visit primary
care facilities for common ailments to have reliable ac-
cess to essential medicines after 2009. However, the
availability of LPGs in secondary and tertiary facilities
and private sectors remains relatively low (32.6 % and
42.9 % respectively). Minimal changes can be observed
when compared the availabilities of LPGs in secondary
and tertiary facilities for 21 common medicines surveyed
in Shandong before the reform (28.82 %) [16] and in this
survey after the reform (30.53 %), which reflects a failure
to implement the policy in these levels. Three reasons
might explain for the finding. First, secondary and tertiary
facilities and private sector outlets are not willing to pro-
cure cheap LPGs. The “drug-maintaining-medicine” sys-
tem in China permits hospitals to add a 15 % markup to
the wholesale prices of drugs. Therefore, the lower the
procurement price, the lower the revenue from the
markup. While private pharmacies are difficult to main-
tain operations by selling overmuch LPGs. Second, phar-
maceutical enterprises might be reluctant to promote
LPGs to secondary and tertiary facilities and private sec-
tors as well. LPGs are regulated by the NEMS to maintain
Table 2 Availability of medicines in public hospitals and retail
pharmacies
Primary healthcare






IB 11.50 % 36.80 % 18.70 %
LPG 100.00 % 32.60 % 42.90 %
IB, Innovator Brand
LPG, Lowest Priced Generic






IB LPG IB LPG
Primary healthcare
facilities (n = 12)
3.76 1.26 27.22 1.66
Secondary and tertiary
healthcare facilities (n = 13 )
6.78 1.98 16.72 2.05
Retail pharmacies (n = 38) 4.13 1.81 4.01 1.82
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low prices, which imply low profit margins, yet massive
marketing expenses are necessitated to propel the use of
them in these sectors. Third, physician inclination to pre-
scribe IBs is also a critical factor. Physicians believe that
the quality and efficacy of IBs are higher than those of
LPGs are. Admittedly, physicians can also obtain sizeable
commissions from medical representatives on prescrip-
tions of IBs. According to a study, 80 % of medicines in
China are sold in hospitals [17], suggesting that public
hospitals are core players in the medicine supply chain.
Hence, the availability of LPGs in secondary and tertiary
facilities must be improved. Essential medicines are
expected to be preferentially stock and used in public
hospitals.
Low availability of IBs can be observed in both public
and private sectors as well, particularly in primary
healthcare facilities and private pharmacies. Limited ac-
cess to IBs in primary facilities can be attributed to
Chinese health policy to increase the proportion of LPGs
in primary facilities, to decrease health expenditures and
to improve drug affordability for the public, whereas the
low availability of IBs in private pharmacies conforms to
patients’ consumption habits. Because purchasing most
IBs from private pharmacies requires a physician’s
Table 4 Affordability of core medicines for common diseases in public hospitals and retail pharmacies







Asthma: IB NA NA 35.31 1.10 NA NA
Salbutamol inhaler LPG 15.33 0.50 21.80 0.70 18.55 0.60
0.1 mg/dose*200 doses
Diabetes: IB NA NA 6.87 0.20 NA NA
GlIBenclamide LPG 1.75 0.10 3.05 0.10 2.61 0.10
5 mg*2*30 days
Hypertension: IB NA NA NA NA NA NA
Atenolol LPG 3.78 0.10 4.62 0.10 4.17 0.10
50 mg*1*30 days
Hypertension: IB 13.66 0.40 9.71 0.30 17.66 0.60
Captopril LPG 7.84 0.30 9.71 0.30 8.74 0.30
25 mg*2*30 days
Hypercholesterola emia: IB 228.71 7.40 336.19 10.80 221.58 7.10
Simvastatin LPG 12.80 0.40 NA NA 25.65 0.80
20 mg*1*30 days
Depression: IB NA NA 20.02 0.70 18.98 0.70
Amitriptyline LPG 11.90 0.40 NA NA 13.65 0.50
25 mg*3*30 days
Adult respiratory infection: IB 11.90 0.40 14.36 0.50 12.63 0.40
Ciprofloxacin LPG 5.03 0.20 NA NA 5.54 0.20
500 mg*2*7 days
Adult respiratory infection: IB NA NA 45.39 1.50 43.28 1.40
Amoxicillin LPG 20.94 0.70 23.68 0.80 22.39 0.80
500 mg*3*7 days
Arthritis: IB NA NA 62.40 2.00 NA NA
Diclofenac LPG 15.89 0.60 15.89 0.60 14.36 0.50
50 mg*2*30 days
Ulcer: IB 24.28 0.80 28.34 0.90 25.93 0.80
Omeprazole LPG 10.43 0.30 12.65 0.40 11.55 0.40
20 mg*1*30 days
Note: NA, not available
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prescription in China, patients prefer to obtain drugs
directly from public hospitals when seeing a physician.
To address the poor availability of both IBs and LPGs
in secondary care, tertiary care and private facilities, a
more specific guidance for preferential use of essential
medicines in these facilities should be issued by the gov-
ernment to improve people’s access to them. Further-
more, mechanisms for reimbursement of the use of
essential medicines in secondary, tertiary and private
levels from the government are indispensable to ensure
a much higher availability as well. Most importantly, the
“drug-maintaining-medicine” system prevalent in these
years should be eliminated in secondary and tertiary sec-
tors to enhance physicians’ willingness to procure and
prescribe LPGs, while additional medicine service fees
and more government investment can be alternatives to
keep these hospitals running.
Little difference is found among medicine outlets
when comparing the prices of LPGs to their IRPs. Be-
cause LPGs of the same medication do not vary obvi-
ously in quality or efficacy and are manufactured by
numerous pharmaceutical firms in China, these enter-
prises depend on price advantages to survive under the
tremendous pressure of market competition. Thus, the
prices of LPGs are low. Only one medication, nifedipine
sustained-release, was found to have a much higher
price than its IRP in all surveyed sectors. The higher
price of this drug is due to its sustained-release function,
which ordinary nifedipine does not possess, and the lack
of competition in the market.
The MPRs of medications on the core list of IBs
available in both sectors were generally higher in the
public sector than in the private sector (median MPRs
were 6.78 and 4.13 for the public and private sectors,
respectively). This finding is similar to that in the stud-
ies conducted in Hubei and Shaanxi (core list MPRs
were 1.05 and 1.84 for the public sector and 0.51 and
1.46 for the private sector in Hubei and Shaanxi, re-
spectively) [7, 18]. The high prices of IBs in the public
sector can be attributed to the abovementioned “drug-
maintaining-medicine” system. Though the Chinese
government has released a varied mix of policies de-
signed to reduce drug prices over the past decade, no
substantial effects have been produced [19]. On the
contrary, private pharmacies choose to reduce medicine
prices to attract customers and remain competitive in
the pharmaceutical market; hence, the price differences
increase. In Thailand, analyses revealed that the MPR
for IBs was higher in the private sector (11.60) than in
the public sector (4.36) [20]. This difference in prices
might be a reason for the difference in the healthcare
policies of Thailand and China.
Regarding the interpretation of affordability, caution
should be exercised when extrapolating the findings to
the national level because there may be regional differ-
ences in affordability due to differences economic devel-
opment across the country. The data from this survey
show that most LPGs for standard treatments are afford-
able; this affordability can be explained by the increased
living standards of residents, which enable them to af-
ford high medical expenses. Statistics show that only 2 %
of the population in Jiangsu lives below the poverty line,
a proportion ranking third in China and higher than
the national average. Moreover, full medical insurance
coverage in Jiangsu Province also protects residents
from the high costs of obtaining medical services. A
comparative analysis of the affordability of IBs and
LPGs indicates that the former are less affordable than
the latter. Though IBs will gradually lose their market
competitiveness given the increasing prevalence of es-
sential medicines, their brand status is not replaceable
over a relatively short period. Thus, it is indispensable
to continue to pay attention to the affordability of IBs.
The present study has two limitations. First, the data
are available only for the day they were collected at each
facility in five cities of Jiangsu Province and may not re-
flect average monthly or yearly availability of medicines.
Another is that calculating affordability based on un-
skilled government worker wages may lead to overly
optimistic results because a portion of the national
population earns less than that wage.
Conclusions
In Jiangsu Province, the high availability of LPGs in pri-
mary care facilities reflects the success of the govern-
ment’s drug policy, whereas their low availability in
secondary and tertiary levels and private pharmacies re-
flects failure to implement this policy at these levels.
The national essential medicine policy should be fully
developed and enforced at the secondary and tertiary
levels and in the private pharmacies of the Chinese
health system to ensure equitable access to basic health
services, particularly for the poor.
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